Citations

Clear

1727 citation(s) found for "Fu, Alan".

Soccer player with unusual right shoulder and arm pain and swelling
Zakaria, Alan, Gill, J., Nishi, Livia Maruoka, Nadwodny, Jeff, Gill, Jasper, Pujalte, George G.A.

Mayo Clinic

The Journal of Primary Health Care | June 29, 2020 | Volume: 12 | Issue: 2 | Pages: 181-183

10.1071/hc19101 | PMID 32594986 Get It

ABSTRACT INTRODUCTION Paget-Schroetter syndrome, or effort thrombosis, refers to a deep venous thrombosis in an upper extremity. It is most commonly located in the axillary or subclavian veins and is associated with vigorous repetitive movements and anatomic abnormalities. CASE PRESENTATION This case study describes an 18-year-old Division 1 soccer player who presented with worsening axillary swelling and pain. He was found to have subclavian stenosis at the level of the thoracic inlet between the clavicle and first rib, with deep venous thrombosis in his right axillary, subclavian, proximal brachial, and basilic veins. It was diagnosed with ultrasound and confirmed with venography. He was treated initially with enoxaparin and warfarin before having mechanical thrombolysis, balloon venoplasty, infusion of tissue plasminogen activator, and a right first rib resection. CONCLUSION As Paget-Schroetter syndrome is rare, early recognition and management leads to fewer long-lasting sequelae and less morbidity. Left untreated, it can result in pulmonary embolism and residual upper extremity obstruction.
Injectable Electrical Conductive and Phosphate Releasing Gel with Two-Dimensional Black Phosphorus and Carbon Nanotubes for Bone Tissue Engineering
Liu, Xifeng , George, Matthew N. , Li, Linli , Gamble, Darian, Gaihre, Bipin , Waletzki, Brian E., Lu, Lichun , Miller Ii, A Lee, Lu, Lichun , Miller, Alan Lee

Mayo Clinic

ACS Biomaterials Science & Engineering | June 25, 2020 | Volume: 6 | Issue: 8 | Pages: 4653-4665

10.1021/acsbiomaterials.0c00612 | PMID 33455193 Get It

Genome-Wide Gene–Diabetes and Gene–Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia
Tang, Hongwei, Jiang, Lai , Arslan, Alan A. , Bracci, Paige M. , Brennan, Paul , Canzian, Federico , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Campa, Daniele , Childs, Erica J., Fuchs, Charles S. , Gaziano, J. Michael , Hartge, Patricia, Hassam, Manal H., Holly, Elizabeth A. , Hoover, Robert N. , Hung, Rayjean J. , Kurtz, Robert C. , Lee, I-Min, Ng, Kimmie , Oberg, Ann L. , Peters, Ulrike , Porta, Miquel , Rabe, Kari G. , Rothman, Nathaniel , Scélo, Ghislaine , Sesso, Howard D. , Thompson, Ian M. , Tjønneland, Anne , Trichopoulou, Antonia , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Zeleniuch‐Jacquotte, Anne , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Chatterjee, Nilanjan , Li, Donghui , Arslan, Alan A , Brennan, Paul , Canzian, Federico , Bamlet, William R , Blackford, Amanda , Duell, Eric J , Hung, Rayjean J , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Orlow, Irene , Sesso, Howard D , Tjønneland, Anne , Wactawski-Wende, Jean , Yu, Herbert , Amundadottir, Laufey , Klein, Alison P , Li, Donghui , Chaffee, Kari G. , Visvanathan, Kala , Porta, Miquel , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Stolzenberg‐Solomon, Rachael Z. , Freeman, Laura E. Beane , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Shu, Xiao‐Ou , White, Emily , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Chanock, Stephen Jacob , Duell, Eric J. , Goggins, Michael , Malats, Núria , Milne, Roger L. , Orlow, Irene , Rothman, Nathaniel , Silverman, Debra T. , Wilkens, Lynne R. , Yu, Kai , Ámundadóttir, Laufey T. , Risch, Harvey A. , Klein, Alison P. , Kraft, Peter , Wei, Peng

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 16, 2020 | Volume: 29 | Issue: 9 | Pages: 1784-1791

10.1158/1055-9965.epi-20-0275 | PMID 32546605 Get It

Abstract Background: Obesity and diabetes are major modifiable risk factors for pancreatic cancer. Interactions between genetic variants and diabetes/obesity have not previously been comprehensively investigated in pancreatic cancer at the genome-wide level. Methods: We conducted a gene–environment interaction (GxE) analysis including 8,255 cases and 11,900 controls from four pancreatic cancer genome-wide association study (GWAS) datasets (Pancreatic Cancer Cohort Consortium I–III and Pancreatic Cancer Case Control Consortium). Obesity (body mass index ≥30 kg/m2) and diabetes (duration ≥3 years) were the environmental variables of interest. Approximately 870,000 SNPs (minor allele frequency ≥0.005, genotyped in at least one dataset) were analyzed. Case–control (CC), case-only (CO), and joint-effect test methods were used for SNP-level GxE analysis. As a complementary approach, gene-based GxE analysis was also performed. Age, sex, study site, and principal components accounting for population substructure were included as covariates. Meta-analysis was applied to combine individual GWAS summary statistics. Results: No genome-wide significant interactions (departures from a log-additive odds model) with diabetes or obesity were detected at the SNP level by the CC or CO approaches. The joint-effect test detected numerous genome-wide significant GxE signals in the GWAS main effects top hit regions, but the significance diminished after adjusting for the GWAS top hits. In the gene-based analysis, a significant interaction of diabetes with variants in the FAM63A (family with sequence similarity 63 member A) gene (significance threshold P < 1.25 × 10−6) was observed in the meta-analysis (PGxE = 1.2 ×10−6, PJoint = 4.2 ×10−7). Conclusions: This analysis did not find significant GxE interactions at the SNP level but found one significant interaction with diabetes at the gene level. A larger sample size might unveil additional genetic factors via GxE scans. Impact: This study may contribute to discovering the mechanism of diabetes-associated pancreatic cancer.
ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223
Hurwitz, Mark , Buscombe, John, Jacene, Heather A. , Klitzke, Alan, Lamonica, Dominick , Lu, Yang, Pryma, Daniel A. , Rohren, Eric , Speer, Tod W., Subramaniam, Rathan M. , Thompson, Holly M. , Tomblyn, Michael, Wong, William W. , Xiao, Ying , Banks, Kevin , Brown, Richard K., Lü, Yang

Mayo Clinic

American Journal of Clinical Oncology | June 10, 2020 | Volume: 43 | Issue: 8 | Pages: 539-544

10.1097/coc.0000000000000702 | PMID 32520788 Get It

Aim/Objectives/Background: The goal of therapy with unsealed radiopharmaceutical sources is to provide either cure or significant prolongation of disease-specific survival, and effective reduction and/or prevention of adverse disease-related symptoms or untoward events while minimizing treatment-associated side effects and complications. Radium-223 dichloride (radium-223) is an alpha particle–emitting isotope used for targeted bone therapy. This practice parameter is intended to guide appropriately trained and licensed physicians performing therapy with radium-223. Such therapy requires close cooperation and communication between the physicians who are responsible for the clinical management of the patient and those who administer radiopharmaceutical therapy and manage the attendant side effects. Adherence to this parameter should help to maximize the efficacious use of radium-223, maintain safe conditions, and ensure compliance with applicable regulations. Methods: This practice parameter was developed according to the process described on the American College of Radiology (ACR) website (“The Process for Developing ACR Practice Parameters and Technical Standards,” www.acr.org/ClinicalResources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters of the ACR Commission on Radiation Oncology in collaboration with the American College of Nuclear Medicine (ACNM), the American Society for Radiation Oncology (ASTRO), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). All these societies contributed to the development of the practice parameter and approved the final document. Results: This practice parameter addresses the many factors which contribute to appropriate, safe, and effective clinical use of radium-223. Topics addressed include qualifications and responsibilities of personnel, specifications of patient examination and treatment; documentation, radiation safety, quality control/improvement, infection control, and patient education. Conclusions: This practice parameter is intended as a tool to guide clinical use of radium-223 with the goal of facilitating safe and effective medical care based on current knowledge, available resources and patient needs. The sole purpose of this document is to assist practitioners in achieving this objective.
Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure
Al‐Khatib, Sana M. , Benjamin, Emelia J. , Alonso, Álvaro , Chauhan, Cynthia, Chen, Peng‐Sheng , Curtis, Anne B. , Desvigne‐Nickens, Patrice , Redfield, Margaret M. , Rienstra, Michiel , Rosenberg, Yves , Spertus, John A. , Stevenson, Lynne W. , Hills, Mellanie True , Cooper, Lawton S. , Go, Alan S. , Alonso, Alvaro , Spertus, John A , Rienstra, Michiel , Benjamin, Emelia J , Albert, Christine M. , Ho, Jennifer E. , Lam, Carolyn S.P. , Link, Mark S. , Patton, Kristen K. , Schnabel, Renate B. , Voors, Adriaan A. , Al-Khatib, Sana M.

Mayo Clinic

Circulation | June 8, 2020 | Volume: 141 | Issue: 23 | Pages: 1915-1926

10.1161/circulationaha.119.045204 | PMID 32511001 Get It

The interrelationships between atrial fibrillation (AF) and heart failure (HF) are complex and poorly understood, yet the number of patients with AF and HF continues to increase worldwide. Thus, there is a need for initiatives that prioritize research on the intersection between AF and HF. This article summarizes the proceedings of a virtual workshop convened by the US National Heart, Lung, and Blood Institute to identify important research opportunities in AF and HF. Key knowledge gaps were reviewed and research priorities were proposed for characterizing the pathophysiological overlap and deleterious interactions between AF and HF; preventing HF in people with AF; preventing AF in individuals with HF; and addressing symptom burden and health status outcomes in AF and HF. These research priorities will hopefully help inform, encourage, and stimulate innovative, cost-efficient, and transformative studies to enhance the outcomes of patients with AF and HF.
Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease
Bae, Kyongtae T., Shi, Tiange , Tao, Cheng , Yu, Alan S.L. , Torres, Vicente E. , Perrone, Ronald D. , Chapman, Arlene B., Brosnahan, Godela , Steinman, Theodore I., Braun, William E. , Srivastava, Avantika , Irazabal, María V. , Harris, Peter C. , Landsittel, Douglas , Hogan, Marie C. , Abebe, Kaleab Z , Harris, Peter C , Torres, Vicente E , Yu, Alan S L , Torres, Vicente E , Irazabal, Maria V , Hogan, Marie C

Mayo Clinic

Journal of the American Society of Nephrology | June 2, 2020 | Volume: 31 | Issue: 7 | Pages: 1640-1651

10.1681/asn.2019101121 | PMID 32487558 Get It

Significance Statement Accurate prediction of risk for disease progression is crucial for clinical management of autosomal dominant polycystic kidney disease (ADPKD). The Mayo imaging classification of ADPKD uses height-adjusted total kidney volume (htTKV) and age to identify patients at highest risk. Because the current Mayo classification applies only to patients with typical diffuse cystic disease (class 1) and poorly predicts eGFR decline for the remaining 5%–10% of patients with atypical morphology (class 2), imaging-based risk modeling remains unresolved. The authors report an expanded imaging classification model in which use of a recalculated htTKV value that excludes prominent exophytic cysts improved prediction for eGFR trajectory. Using a recalculated htTKV may allow inclusion of class 2 patients in the Mayo classification of ADPKD and reclassification of class 1 patients with prominent exophytic cysts. Background The Mayo Clinic imaging classification of autosomal dominant polycystic kidney disease (ADPKD) uses height-adjusted total kidney volume (htTKV) and age to identify patients at highest risk for disease progression. However, this classification applies only to patients with typical diffuse cystic disease (class 1). Because htTKV poorly predicts eGFR decline for the 5%–10% of patients with atypical morphology (class 2), imaging-based risk modeling remains unresolved. Methods Of 558 adults with ADPKD in the HALT-A study, we identified 25 patients of class 2A with prominent exophytic cysts (class 2Ae) and 43 patients of class 1 with prominent exophytic cysts; we recalculated their htTKVs to exclude exophytic cysts. Using original and recalculated htTKVs in association with imaging classification in logistic and mixed linear models, we compared predictions for developing CKD stage 3 and for eGFR trajectory. Results Using recalculated htTKVs increased specificity for developing CKD stage 3 in all participants from 82.6% to 84.2% after adjustment for baseline age, eGFR, BMI, sex, and race. The predicted proportion of class 2Ae patients developing CKD stage 3 using a cutoff of 0.5 for predicting case status was better calibrated to the observed value of 13.0% with recalculated htTKVs (45.5%) versus original htTKVs (63.6%). Using recalculated htTKVs reduced the mean paired difference between predicted and observed eGFR from 17.6 (using original htTKVs) to 4.0 ml/min per 1.73 m 2 for class 2Ae, and from −1.7 (using original htTKVs) to 0.1 ml/min per 1.73 m 2 for class 1. Conclusions Use of a recalculated htTKV measure that excludes prominent exophytic cysts facilitates inclusion of class 2 patients and reclassification of class 1 patients in the Mayo classification model.
The impact of genetic mutations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu, Alex John, Ueberroth, Benjamin E. , Tzou, Katherine S., Choo, Richard , Moore, Cassandra N., Keole, Sameer R., Wong, William W. , Liu, Alex J. , Kosiorek, Heidi , Kendi, A. Tuba , Quevedo, Fernando , Ho, Thai H. , Singh, Parminder Pal , Bryce, Alan H.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e17587-e17587

10.1200/jco.2020.38.15_suppl.e17587 Get It

e17587 Background: Radium (Ra)-223 has become the cornerstone treatment in patients with metastatic castrate-resistant prostate cancer (mCRPC) with bone metastases. Ra-223 has been shown to suppress abnormal bone formation by inducing DNA double-strand breaks in tumor cells. This can reduce skeletal-related events, as well as improve survival and quality of life. Studies have indicated mutations that regulate DNA damage response in prostate cancer as susceptible to PARP inhibitors and platinum-based therapies. This study aims to evaluate mCRPC response to Ra-223 stratified by tumor genomics. Methods: This is a retrospective study of mCRPC patients who received Ra-223 and genetic testing within the Mayo Clinic database (Arizona, Florida, and Minnesota). Patient demographics, genetic mutations, treatment responses in terms of alkaline phosphatase (ALP) and prostate-specific antigen (PSA), and survival were assessed. Primary end points were progression-free survival (PFS) and overall survival (OS) from time of first radium treatment. Results: 239 mCRPC patients treated with Ra-223 were identified. Germline and/or somatic genetic sequencing was available in 50 patients, who had a median age of 61 years at time of diagnosis and 68 years at time of Ra-223 treatment. Median Gleason score at time of diagnosis was 8.0. 100% of patients received prior androgen deprivation therapy. 72% received prior docetaxel, and 18% received prior cabazitaxel. Notable mutations included TP53 (45.2%), TMPRSS2-ERG (28.6%), PTEN (26.2%), BRCA1/2 (14.3%), ATM (9.3%), CDK12 (7.1%), and Rb (4.9%). TMPRSS2-ERG was the second most commonly found mutation, with median OS 12.7 mo versus 15.4 mo in patients without TMPRSS2-ERG mutations (p = 0.099). In patients with CDK12 mutations (2 of 28 tested positive), PFS was 10.4 mo versus 5.6 mo in patients without CDK12 mutations (p = 0.157). The assessment of ALP and PSA response to radium treatment stratified by genetic mutation did not reach statistical significance. Conclusions: Among mCRPC patients treated with Ra-223 at Mayo Clinic, TMPRSS2-ERG was the second most commonly found genetic mutation and had observed worse survival outcomes that approached statistical significance. Prospective studies and increased sample sizes are needed to determine the impact of genetic mutations in response to Ra-223.
Addition of carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in post-second generation hormone therapy setting: Does it improve treatment response and survival outcomes?
Alamiri, Jamal, Andrews, Jack R. , Alom, Manaf, Motterle, Giovanni , Higa, Julianna , Karnes, J., Kwon, Eugene D., Higa, Julianna L , Ahmed, Mohamed E. , Bryce, Alan H.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e17540-e17540

10.1200/jco.2020.38.15_suppl.e17540 Get It

e17540 Background: The clinical course in metastatic castrate-resistant prostate cancer (mCRPC) can be complicated when patients have disease progression after treatment with 2nd generation hormone therapy (2nd-HT), such as enzalutamide or abiraterone. Currently, limited data exist regarding the optimal choice of chemotherapy for mCRPC after failing 2nd-HT. We sought to evaluate three common chemotherapy regimens in this setting. Methods: We retrospectively identified 150 patients with mCRPC with disease progression on enzalutamide or abiraterone. 92 patients were chemo-naïve, while 58 patients had previously received docetaxel chemotherapy prior to 2nd-HT. After failing 2nd-HT, 90 patients received docetaxel-alone (group A), 33 patients received carboplatin plus docetaxel (group B), while 27 patients received cabazitaxel-alone (Group C). Favorable response was defined by ≥50% reduction in PSA level from baseline after a complete course of chemotherapy. Survival outcome was assessed for 30-month overall survival. Results: Mean (SD) age was 71.2 (8.28), 69.5(8.38) and 67.2 (8.36) for group (A), (B) and (C), respectively. Mean (SD) pre-chemotherapy PSA was 63.8 (138.18), 58.5 (118.15) and 53.7 (88.15) for group (A), (B) and (C), respectively. Mean (SD) Gleason score was 7.9 (1.1), 8.4 (0.88) and 8.1 (1.06) for group (A), (B) and (C), respectively. Patients in group (B) were 2.6 times more likely to have a favorable response compared to group (A) (OR = 2.625, 95%CI: 1.15 - 5.99) and almost 3 times compared to patients in group (C) (OR = 2.975, 95%CI: 1.04 – 8.54) (p-value = 0.0442). We report a Hazard Ratio (HR) of 3.1 (95% CI 1.31-7.35; p = 0.0037) between patients in group (A) versus group (B), and a HR of 4.18 (95% CI 1.58-11.06; p = 0.0037) between patients in group (C) versus group (B). Thirty-month overall survival was 70.7%, 38.9%, and 30.3% for group (B), (A), and (C) respectively (p-value = 0.008). Conclusions: Our data demonstrate improved response and cancer-specific survival in patients with treatment-refractory mCRPC on docetaxel plus carboplatin compared to docetaxel or cabazitaxel alone. Selection bias is inherent in any retrospective study; however, our finding suggests that clinicians may consider docetaxel plus carboplatin in mCRPC patients who fail 2nd-HT. Further prospective studies are warranted.
Treatment of metastatic castration sensitive prostate cancer (mCSPC) by disease volume: A systematic review and a meta-analysis.
Sipra, Qurat Ul Ain Riaz , Asghar, Noureen, Adil, Shahroz, Raina, Ammad, Maheswari, Deepa, Riaz, Irbaz Bin , Siddiqi, Rabbia , Hwang, Steven R. , Husnain, Muhammad , Babiker, Hani M. , Murad, M. Hassan , Singh, Parminder Pal , Bryce, Alan H.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e17539-e17539

10.1200/jco.2020.38.15_suppl.e17539 Get It

e17539 Background: Chemotherapy with Docetaxel (D) or androgen pathway inhibition (API) with Abiraterone Acetate plus prednisone (AAP), Aplautamide(APA) and Enzalutamide(E) are acceptable, FDA approved treatment options for mCSPC. It is not clear whether the magnitude of benefit varies by the choice of initial agent [chemotherapy vs API] or by volume of disease [High vs Low]. Data is now available from all registration trials by volume status and motivated this analysis to inform initial treatment choice in mCSPC. Methods: We systematically searched MEDLINE(Ovid), Embase, and Scopus for randomized controlled trials of chemotherapy(D) or APIs (AAP, APA, ENZ) that had available hazard ratios (HRs) for overall survival (OS) and Progression Free Survival (PFS) according to patient’s volume of disease. We also reviewed abstracts and presentations from all major conference proceedings. We calculated the pooled overall survival HR and 95% CI by chemotherapy and APIs and by high volume(HVD) and low volume(LVD) using a random effect model, and tested for heterogeneity to assess the null hypothesis that no difference in the survival advantage exists by choice of initial agent and volume of disease. Results: Of 4456 studies identified in our search, there were 8 eligible randomized controlled trials that were included in the analysis. Both D and APIs significantly improved PFS [HR 0.48; 0.45-0.51] and OS [0.72; 0.64-0.81] when added to ADT, however the latter was associated with significantly higher improvement in PFS( P < 0.01) and OS (P = 0.03). In patients treated with D, patients with HVD derive significantly more benefit as compared to LVD( P = 0.046) and patients treated with APIs both HVD and LVD patients derive similar benefit( P = 0.80) (Table). Conclusions: mCSPC patients derive higher magnitude of survival benefit when treated with APIs as compared to D; however, D may be preferred in HVD patients. [Table: see text]
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
Alamiri, Jamal, Andrews, Jack R. , Dundar, Ayca , Motterle, Giovanni , Karnes, J., Kwon, Eugene D., Bold, Michael S., Ahmed, Mohamed E. , Bryce, Alan H. , Kendi, A. Tuba

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 5577-5577

10.1200/jco.2020.38.15_suppl.5577 Get It

5577 Background: Prostate specific antigen (PSA) has well-recognized limitations as a marker for treatment response and disease progression. A post hoc analysis of the PREVAIL trial reported 24.5% of chemotherapy naïve mCRPC patients on enzalutamide had radiographic progression on conventional imaging with non-rising PSA. In this study, we sought to retrospectively compare PSA levels with C-11 choline positron emission tomography/ computed tomography (PET/CT) images in patients with m-CRPC on 2nd-HT with prior use of chemotherapy. Methods: We identified 123 patients with mCRPC on 2nd-HT following prior use of docetaxel chemotherapy (Abiraterone, n = 106; Enzalutamide, n = 17). Patients underwent serial PSA testing and C-11 choline PET/ CTs every 3–6 months. Disease progression was defined by the increase in blood pool corrected maximum standardized uptake value (SUVmax) of the index lesion on C-11 choline PET/CT scan. Suspicious lesions were confirmed by biopsy and/or conventional imaging. Results: Approximately 43% (n = 53) of patients had radiographic disease progression while on 2nd-HT. At time of radiographic progression, 60.4% of patients showed a parallel rise in PSA (Group-A), while 39.6% showed a paradoxical response; defined as radiographic progression with stable or down-trending PSA (Group-B). Median PSA at time of progression was 3.1 ng/ml for Group-A, and 1.3 ng/ml for Group-B (p-value = 0.0176). Median SUVmax was the same (4.9 Group-A, 4.6 Group-B; p-value = 0.6072). Bone-predominance progression was more significant in Group-B (90%) versus Group-A (65%) (p-value = 0.0309). The median time for radiographic progression was 9.5 months versus 3.9 months for Group-A and Group-B, respectively (Log-Rank = 0.0063). Conclusions: Metabolic imaging is a useful tool that should complement PSA in the evaluation of treatment response and disease progression in mCRPC patients on 2nd-HT, especially considering the paradoxical response observed in our data.